

FOR IMMEDIATE RELEASE

***ASAIO JOURNAL* LAUNCHES BIOHYBRID SECTION & CALL FOR PAPERS**

Baltimore, MD—*ASAIO Journal* Editor-in-Chief Mark S. Slaughter, MD is proud to announce the addition of a Biohybrid section to its editorial content beginning with the first issue of 2016. The Biohybrid section will provide authors a place to publish research focusing on the successful fusion of medical technology and biological improvement.

[*ASAIO Journal*](#), the official journal of [ASAIO](#) (American Society for Artificial Internal Organs), will apply ASAIO's 55+ years of expertise in treatment of organ failure to the task of translating discovery science in cell biology to cost-effective treatments for patients with organ failure.

William H. Fissell, MD (Vanderbilt University) and Bettina Wiegmann, MD (Hannover Medical School) will serve as co-Section Editors. They are excited about this new initiative in *ASAIO Journal*, which will build on the traditional focus of ASAIO--artificial organs—with every kind of cellular and biological components, to optimize the effectiveness and long-term use of these artificial organs in each and every aspect.

Both editors agree that now is the time to launch a dedicated Biohybrid Section in the journal. Dr. Wiegmann notes that “within the last decades artificial organs could successfully be implemented in the clinical setting, but only for a temporary, almost exclusively supportive way.” However, advancements in technology have overcome limitations to the degree that, as Dr. Fissell states, “we now have entered an era in which the failure of organs with synthetic and catabolic function now may be treatable with engineered devices.”

The editors invite submission of original research articles and Review articles related to Biohybrid advances. Dr. Fissell says that “we look forward to studies that describe advances in engineered stroma, vascular, neural, and lymphatic connections between engineered tissues and hosts, strategies to monitor artificial organ function, and strategies for life-cycle management of artificial organs with living tissue.” Submissions should explore the mechanisms by which the cellular components of engineered solutions to organ failure integrate with the scaffolds, substrates, and packages by which they are delivered to the patient. Manuscripts will undergo normal peer review as they are received. Manuscripts can be submitted for peer review to <http://asaio.edmgr.com/>.

The cross-disciplinary Biohybrid section will span and inform multiple organ engineering efforts and will allow the idea of Biohybrid organs to come closer to reality.

###

About *ASAIO Journal*

The mission of [ASAIO Journal](#), the official journal of [ASAIO](#) (American Society for Artificial Internal Organs), is in the forefront of artificial organ research and development. On the cutting edge of innovative technology, it features peer-reviewed articles of the highest quality that describe research, development, the most recent advances in the design of artificial organ devices and findings from initial testing. The *ASAIO Journal* features state-of-the-art investigations, laboratory and clinical trials, and discussions and opinions from experts around the world.

About ASAIO (American Society for Artificial Internal Organs)

[ASAIO](#) promotes the development, application and awareness of organ technologies which enhance quality and duration of life. For more than 55 years its mission has been to provide a forum that globally and collaboratively promotes the development of innovative medical device technology at the crossroads of science, engineering, and medicine. Membership is comprised of clinicians, scientists, engineers, industry, academia, the financial community, as well as representatives from the Food & Drug Administration, National Science Foundation and the National Institutes of Health. ASAIO members have created medical device industries and academic successes that have led to many of the leading-edge devices used to treat patients today for renal (dialysis), cardiac (ventricular assist devices), pulmonary (ECMO and respiratory assist), hepatic (liver assist), pancreatic (artificial pancreas) and neurologic (brain-motor prostheses) applications. ASAIO is focused on creating revolutionary therapies for organ failure, including bioartificial and hybrid organs, bionics, as well as cell and genetic therapies. Through the work of its 700 members, the Annual Conference, the peer reviewed ASAIO Journal, and close cooperation with other international societies, ASAIO provides opportunities for young investigators interested in medical device development to interact with established experts and sponsoring companies. Due largely to ASAIO and its members, artificial hearts, lungs, kidneys, blood vessels and joints are now in common practice and entire new fields of clinical medicine have emerged in the fields of nephrology, cardiac and vascular surgery, transplantation and intensive care.

About KWF-Editorial Services

The *ASAIO Journal* editorial office is managed by KWF Editorial Services, LLC, a leading editorial services provider to the scholarly publishing community. Our staff of more than 70 experienced editors provides a full range of editorial services including managing editor services, day-to-day manuscript processing through the peer review process, low and high-volume work flow management, social media and CME support, and production services. We provide a customized, cost-effective, virtual back office that supports your existing journal operations. Our key competencies are in-depth knowledge of peer review best practices, management professionalism, superior customer service to all journal constituencies, and rapidly scalable staffing. KWF Editorial Services is the sister company of [Kaufman Wills Fusting & Co](#), the leading management consultancy serving the scholarly publishing community.

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depository Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwer.com, follow [@WKHealth](#) or [@Wolters_Kluwer](#) on Twitter, like us on [Facebook](#), follow us on [LinkedIn](#), or follow WoltersKluwerComms on [YouTube](#).

CONTACT:

Mark S. Slaughter, MD, Editor-in-Chief

Michelle Gaffney, Managing Editor

ASAIO Journal

Phone: 443-685-5413

Email: asaio.journal@gmail.com

Journal Website: www.asaiojournal.com

Submission Site: <http://asaio.edmgr.com/>